Skip to main content

Advertisement

SpringerLink
Log in

Changes in Oncogene Expression in Experimental Glioblastoma 101.8 Rats during Therapy with PLGA Nanoparticles Loaded with Doxorubicin

  • CELL TECHNOLOGIES IN BIOLOGY AND MEDICINECELL MEDICINE
  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

We compared the expression of the main glioblastoma oncogenes during therapy with doxorubicin (Dox) and Dox in nanoparticles based on a copolymer of lactic and glycolic acids (Dox-PLGA) at a delayed start of treatment. Late initiation of Dox-PLGA therapy of glioblastoma showed an increase in the expression of multiple drug resistance genes, such as Abcb1b and Mgmt, and a decrease in Sox2 expression. Increased expression of other oncogenes (Melk, Wnt3, Gdnf, and Pdgfra) were observed during both Dox and Dox-PLGA therapy. These changes indicate increased tumor aggressiveness and its resistance to cytostatics at the late start of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S. Survival analysis of glioblastoma multiforme. Asian Pac. J. Cancer Prev. 2018;19(9):2613-2617. https://doi.org/10.22034/APJCP.2018.19.9.2613

  2. Voulgaris S, Partheni M, Karamouzis M, Dimopoulos P, Papadakis N, Kalofonos HP. Intratumoral doxorubicin in patients with malignant brain gliomas. Am. J. Clin. Oncol. 2002;25(1):60-64. https://doi.org/10.1097/00000421-200202000-00013

    Article  PubMed  Google Scholar 

  3. Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discov. Today. 2017;22(2):270-281. https://doi.org/10.1016/j.drudis.2016.11.005

    Article  CAS  PubMed  Google Scholar 

  4. Li XR, Cheng XH, Zhang GN, Wang XX, Huang JM. Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. J. Ovarian Res. 2022;15(1):96. https://doi.org/10.1186/s13048-022-01029-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kikuchi T, Saito R, Sugiyama S, Yamashita Y, Kumabe T, Krauze M, Bankiewicz K, Tominaga T. Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models. J. Neurosurg. 2008;109(5):867-873. https://doi.org/10.3171/JNS/2008/109/11/0867

    Article  CAS  PubMed  Google Scholar 

  6. Hekmatara T, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, Matschke J, Gelperina S, Kreuter J, Glatzel M. Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects. Clin. Neuropathol. 2009;28(3):153-164. https://doi.org/10.5414/npp28153

    Article  CAS  PubMed  Google Scholar 

  7. Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, Glatzel M, Kreuter J. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One. 2011;6(5):e19121. https://doi.org/10.1371/journal.pone.0019121

  8. Tsvetkov IS, Zolotova NA, Kosyreva AM, Dzhalilova DSh, Kudelkina VV, Chernikov VP, Mkhitarov VA, Mikhailova LP, Soboleva NI, Razzhivina VA, Dobrynina MT, Gelperina SE, Makarova OV. Morphological characteristics of nephrotoxicity of doxorubicin and doxorubicin PLGA-nanoparticle. Klin. Eksper. Morfol. 2021;10(S4):77-86. Russian. https://doi.org/10.31088/CEM2021.10.S4.77-86

  9. Liang J, Lv X, Lu C, Ye X, Chen X, Fu J, Luo C, Zhao Y. Prognostic factors of patients with gliomas — an analysis on 335 patients with glioblastoma and other forms of gliomas. BMC Cancer. 2020;20(1):35. https://doi.org/10.1186/s12885-019-6511-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ko CC, Yeh LR, Kuo YT, Chen JH. Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomark. Res. 2021;9(1):52. https://doi.org/10.1186/s40364-021-00306-8

    Article  PubMed  PubMed Central  Google Scholar 

  11. Dempsey MF, Condon BR, Hadley DM. Measurement of tumor “size” in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am. J. Neuroradiol. 2005;26(4):770-776.

    PubMed  PubMed Central  Google Scholar 

  12. Maksimenko O, Malinovskaya J, Shipulo E, Osipova N, Razzhivina V, Arantseva D, Yarovaya O, Mostovaya U, Khalansky A, Fedoseeva V, Alekseeva A, Vanchugova L, Gorshkova M, Kovalenko E, Balabanyan V, Melnikov P, Baklaushev V, Chekhonin V, Kreuter J, Gelperina S. Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: Towards the pharmaceutical development. Int. J. Pharm. 2019;572:118733. https://doi.org/10.1016/j.ijpharm.2019.118733

  13. Khalansky AS, Kondakova LI. Transplanted rat glioma 101.8.I. Biological characteristics. Klin. Eksper. Morfol. 2013;(4):63-68. Russian.

  14. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol. 2009;20(1):175-181. https://doi.org/10.1093/annonc/mdn548

    Article  CAS  PubMed  Google Scholar 

  15. Caldera V, Mellai M, Annovazzi L, Monzeglio O, Piazzi A, Schiffer D. MGMT hypermethylation and MDR system in glioblastoma cancer stem cells. Cancer Genomics Proteomics. 2012;9(4):171-178.

    CAS  PubMed  Google Scholar 

  16. Othman RT, Kimishi I, Bradshaw TD, Storer LC, Korshunov A, Pfister SM, Grundy RG, Kerr ID, Coyle B. Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathol. Commun. 2014;2:57. https://doi.org/10.1186/2051-5960-2-57

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ, Lam EW. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol. Cancer Ther. 2008;7(3):670-678. https://doi.org/10.1158/1535-7163.MCT-07-0397

    Article  CAS  PubMed  Google Scholar 

  18. Yang N, Wang Y, Hui L, Li X, Jiang X. Silencing SOX2 expression by RNA interference inhibits proliferation, invasion and metastasis, and induces apoptosis through MAP4K4/JNK signaling pathway in human laryngeal cancer TU212 cells. J. Histochem. Cytochem. 2015;63(9):721-733. https://doi.org/10.1369/0022155415590829

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Caglayan D, Lundin E, Kastemar M, Westermark B, Ferletta M. Sox21 inhibits glioma progression in vivo by forming complexes with Sox2 and stimulating aberrant differentiation. Int. J. Cancer. 2013;133(6):1345-1356. https://doi.org/10.1002/ijc.28147

    Article  CAS  PubMed  Google Scholar 

  20. Taylor JT, Ellison S, Pandele A, Wood S, Nathan E, Forte G, Parker H, Zindy E, Elvin M, Dickson A, Williams KJ, Karabatsou K, McCabe M, McBain C, Bigger BW. Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma. Neuro Oncol. 2020;22(9):1289-1301. https://doi.org/10.1093/neuonc/noaa051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yu W, Ren X, Hu C, Tan Y, Shui Y, Chen Z, Zhang L, Peng J, Wei Q. Glioma SOX2 expression decreased after adjuvant therapy. BMC Cancer. 2019;19(1):1087. https://doi.org/10.1186/s12885-019-6292-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. B. V. Pet-rovsky Russian Research Center of Surgery, A. P. Avtsyn Research Institute of Human Morphology, Moscow, Russia

    A. I. Alekseeva, A. D. Gerasimov, V. V. Kudelkina, A. M. Kosyreva & T. Kh. Fatkhudinov

  2. Institute of Higher Nervous Activity and Neurophysiology, Moscow, Russia

    G. V. Pavlova

  3. D. I. Mendeleev University of Chemical Technology of Russia, Moscow, Russia

    N. S. Osipova

  4. N. N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, Moscow, Russia

    S. F. Drozd & G. V. Pavlova

Authors
  1. A. I. Alekseeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. D. Gerasimov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. V. Kudelkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. S. Osipova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. F. Drozd
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. V. Pavlova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. M. Kosyreva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Kh. Fatkhudinov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. I. Alekseeva.

Additional information

Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 4, pp. 207-211, December, 2022

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alekseeva, A.I., Gerasimov, A.D., Kudelkina, V.V. et al. Changes in Oncogene Expression in Experimental Glioblastoma 101.8 Rats during Therapy with PLGA Nanoparticles Loaded with Doxorubicin. Bull Exp Biol Med 174, 518–522 (2023). https://doi.org/10.1007/s10517-023-05740-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-023-05740-2

Key Words

Search

Navigation